carboplatin,durvalumab,edit-301,paclitaxel,olaparib,pembrolizumab,bevacizumab
editas medicine, inc.,astrazeneca,merck,roche
['gynca', 'duo-o', 'gyn', 'ovarian', 'ruby', 'keynote826']
io+ct in 1st line setting across all #gyncancers at #asco23 #cervicalcancer : outstanding final results of keynote826trial #endometrialcancer : bicr survival data of rubystudy #ovariancancer : 1st positive results with io even in hrd negative population from duo-ostudy 
PostDoctoral Fellow at @NCICCR_WMB NIH/NCI, Bethesda, MD, U.S. | OB/GYN Resident at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy #gynonc